🇺🇸 FDA
Patent

US 8273869

Lipid formulated dsRNA targeting the PCSK9 gene

granted A61KA61K31/713A61K38/1709

Quick answer

US patent 8273869 (Lipid formulated dsRNA targeting the PCSK9 gene) held by Alnylam Pharmaceuticals, Inc. expires Mon Sep 20 2032 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Alnylam Pharmaceuticals, Inc.
Grant date
Tue Sep 25 2012 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Sep 20 2032 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
27
CPC classes
A61K, A61K31/713, A61K38/1709, A61K47/545, A61K47/55